Trial reportAmerican journal of respiratory and critical care medicine2010
Viral load drives disease in humans experimentally infected with respiratory syncytial virus.
Trial report in American journal of respiratory and critical care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02484417 (A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers), which is not on this map. Cited by 182 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers
Who cites it
182 citing papers in PubMed, 4 syntheses or guidelines pooled it, 333 citations in OpenAlex.
- Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.British journal of clinical pharmacology · 2021Pooled it
- Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.Epidemics · 2021Pooled it
- [Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2019Pooled it
- The Human Immune Response to Respiratory Syncytial Virus Infection.Clinical microbiology reviews · 2017Pooled it
- Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.The Journal of infectious diseases · 2023Trial
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.The Journal of infectious diseases · 2022Trial
- Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.The Journal of infectious diseases · 2022Trial
- A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.The Journal of clinical investigation · 2021Trial
- A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.Antimicrobial agents and chemotherapy · 2020Trial
- Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection.The Journal of clinical investigation · 2020Trial
- Viral load is strongly associated with length of stay in adults hospitalised with viral acute respiratory illness.The Journal of infection · 2016Trial
- Trial
- Trial
- Trial
- Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.American journal of respiratory and critical care medicine · 2015Trial
- RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.The Journal of clinical investigation · 2014Trial
- Diesel exhaust exposure and nasal response to attenuated influenza in normal and allergic volunteers.American journal of respiratory and critical care medicine · 2012Trial
- Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy.CPT: pharmacometrics & systems pharmacology · 2026Article
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 9 institutions in 2 countries.
Funding
Abstract
rationaleRespiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking. Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load.
objectivesThe development of a human experimental wild-type RSV infection model to address these challenges.
methodsHealthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0-5.4 log plaque-forming units/person) of wild-type RSV-A intranasally. MEASUREMENTS AND MAIN
resultsOverall, 77% of volunteers consistently shed virus. Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received. Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined. Viral loads correlated significantly with intranasal proinflammatory cytokine concentrations (IL-6 and IL-8). Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, physical examination, and amount of nasal mucus).
conclusionsViral load appears to drive disease manifestations in humans with RSV infection. The observed parallel viral and disease kinetics support a potential clinical benefit of RSV antivirals. This reproducible model facilitates the development of future RSV therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.